Retatrutide 30mg

Description

Retatrutide 30mg, with the catalog identity made clear

This research listing is identified as Retatrutide 30mg in the product record and analytical documents. It is supplied in a lyophilized vial for qualified laboratory work, with the compound identity, listed quantity, SKU and available analytical documents presented together.

Review the product record and both reports before ordering. The linked documents support a lot-specific evaluation; they are not a substitute for your laboratory’s supplier qualification, acceptance criteria or independent testing.

Product details

Analytical documents

Review the Retatrutide 30mg UPLC/MS report and Retatrutide 30mg endotoxin report in full.

The UPLC/MS report identifies Retatrutide, lists a 30mg specification, and records lot-specific results of 29.75mg and 99.42%. Those figures describe the attached report; they are not presented as a blanket guarantee for every unit or as proof of sterility, safety, suitability or performance.

Both reports display an analysis date of May 4, 2026 and a received date of May 9, 2026. The endotoxin report also shows no printed acceptance specification. These chronology and specification limitations are disclosed so your laboratory can make its own document-review and acceptance decision.

Retatrutide identity and research-status guide

For the standardized substance identifiers, current U.S. research status and a practical report-review workflow, read What Is Retatrutide? Identity, Research Status & COA Review.

Why order from Purity Collective?

Purity Collective presents the Retatrutide identity clearly, then places the listing details and available documents on the same page. Qualified buyers can compare the material with their procurement requirements before checkout.

Choose the appropriate listed quantity

This page is for the 30mg listing. If your procurement record calls for a different listed quantity, compare it with the Retatrutide 10mg listing and confirm the SKU before ordering.

Before you order

• Confirm that Retatrutide, the 30mg listed quantity and SKU PC-RETATRUTIDE-30MG match your procurement request.
• Review both analytical documents, including the compound, lot, dates, methods, specifications and result fields.
• Treat the numerical report values as lot-specific document data, not as a general product or safety claim.
• Apply your laboratory’s own supplier-qualification, acceptance, storage and handling procedures.

Retatrutide 30mg FAQs

What is Retatrutide 30mg?

This research listing is identified as Retatrutide 30mg in the product record and analytical documents. The product record and linked analytical documents identify the compound as Retatrutide.

How does this listing differ from Retatrutide 10mg?

This listing has a 30mg stated quantity and SKU PC-RETATRUTIDE-30MG. The 10mg listing has a different stated quantity, SKU and supporting documents. Confirm the required listing before checkout.

What does the UPLC/MS report show?

The attached report identifies Retatrutide and records lot-specific results of 29.75mg and 99.42%. Review the complete report and its dates rather than treating either number as a standalone acceptance claim.

Are analytical documents available?

Yes. A UPLC/MS report and an endotoxin report are linked above. Both show an analysis date earlier than the received date, and the endotoxin report prints no acceptance specification.

Is Retatrutide 30mg intended for human use?

No. This listing is supplied only for qualified laboratory research and is not for human or veterinary administration. No clinical, therapeutic, dosing or administration guidance is provided.

Research-use notice

For qualified laboratory research only. Not for human or veterinary administration. This listing is not presented as a medicine or treatment.